Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 79
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02252913 | A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer | ||
| NCT02320409 | A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012) | ||
| NCT05318820 | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers | ||
| NCT02966171 | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies | ||
| NCT03483948 | Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | ||
| NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | ||
| NCT05173142 | A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | ||
| NCT03684967 | Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC | ||
| NCT02857998 | A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms | ||
| NCT01955304 | Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects | ||
| NCT02614495 | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | ||
| NCT04923945 | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | ||
| NCT04372407 | A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects | ||
| NCT02267967 | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | ||
| NCT03778229 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | ||
| NCT03977090 | Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | ||
| NCT02691299 | A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT04557397 | Fruquintinib CYP3A Inhibitor and Inducer Study | ||
| NCT04849351 | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | ||
| NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | ||
| NCT01645215 | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | ||
| NCT04755075 | Surufatinib Hepatic Impairment Study | ||
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | ||
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | ||
| NCT03597971 | HMPL004-6599 Phase I Dose-escalating Study | ||
| NCT05511051 | A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | ||
| NCT02590965 | A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT06437353 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | ||
| NCT03128164 | A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed | ||
| NCT02017236 | A Food Effect Phase I Study of the Volitinib in Healthy Subjects | ||
| NCT03951623 | The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients | ||
| NCT04169672 | Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | ||
| NCT05015608 | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification | ||
| NCT04510649 | Surufatinib DDI With a PPI and a CYP3A Inducer | ||
| NCT02314819 | A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO) | ||
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | ||
| NCT02601274 | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | ||
| NCT02976116 | A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT04645940 | Fruquintinib Food Effect and Proton Pump Inhibitor Study | ||
| NCT02601248 | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | ||
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | ||
| NCT04372394 | A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects | ||
| NCT02415023 | A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | ||
| NCT03627520 | A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib | ||
| NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | ||
| NCT01805791 | A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis | ||
| NCT00655733 | Phase II Study of HMPL-004 in Subjects With Crohn's Disease | ||
| NCT03873532 | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients | ||
| NCT03483259 | To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers | ||
| NCT03860532 | Phase I Clinical Trial in Healthy Male Volunteers |
